Results 21 to 30 of about 32,545 (255)

Ginsenoside Rb1 can ameliorate the key inflammatory cytokines TNF-α and IL-6 in a cancer cachexia mouse model

BMC Complementary Medicine and Therapies, 2020
Background Cancer cachexia is a severe condition that leads to the death of advanced cancer patients, and approximately 50~80% of cancer patients have cancer cachexia.
Shuai Lu, Yubo Zhang, Huajun Li, Jing Zhang, Yingqian Ci, Mei Han   +5 more
doaj   +1 more source

The Microbiota and Cancer Cachexia [PDF]

International Journal of Molecular Sciences, 2019
Cancer cachexia is a multifactorial syndrome defined by weight loss, muscle wasting, and systemic inflammation. It affects the majority of patients with advanced cancer and is associated with poor treatment response, early mortality and decreased quality of life.
Kelly M. Herremans, Andrea N. Riner, Miles E. Cameron, Jose G. Trevino   +3 more
openaire   +2 more sources

Oncometabolite D-2-hydroxyglutarate—dependent metabolic reprogramming induces skeletal muscle atrophy during cancer cachexia

Communications Biology, 2023
Cancer cachexia is characterized by weight loss and skeletal muscle wasting. Based on the up-regulation of catabolism and down-regulation of anabolism, here we showed genetic mutation-mediated metabolic reprogramming in the progression of cancer cachexia
Xinting Zhu, Juan Hao, Hong Zhang, Mengyi Chi, Yaxian Wang, Jinlu Huang, Rong Xu, Zhao Xincai, Bo Xin, Xipeng Sun, Jianping Zhang, Shumin Zhou, Dongdong Cheng, Ting Yuan, Jun Ding, Shuier Zheng, Cheng Guo, Quanjun Yang   +17 more
doaj   +1 more source

Bile acid metabolism dysregulation associates with cancer cachexia: roles of liver and gut microbiome

Journal of Cachexia, Sarcopenia and Muscle, 2021
Background Cancer cachexia is a multifactorial metabolic syndrome in which bile acid (BA) metabolism might be involved. The aim of the present study was to clarify the contribution of liver and gut microbiota to BA metabolism disturbance in cancer ...
Lixing Feng, Wanli Zhang, Qiang Shen, Chunxiao Miao, Lijuan Chen, Yiwei Li, Xiaofan Gu, Meng Fan, Yushui Ma, Hui Wang, Xuan Liu, Xiongwen Zhang   +11 more
doaj   +1 more source

Myostatin/Smad2/Smad3 pathway define a differential clinical phenotype in COPD-associated sarcopenia

ERJ Open Research
Background Sarcopenia, defined as the loss of muscle mass and function, represents one of the most relevant comorbidities in patients with COPD even at early stages.
Adriana Núñez-Robainas, Maria Guitart, Adrián López-Postigo, Antonio Sancho-Muñoz, Esther Barreiro   +4 more
doaj   +1 more source

Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study

Journal of Cachexia, Sarcopenia and Muscle, 2023
Background Cancer cachexia is a syndrome that does not fully recover with nutritional support and causes appetite loss and body weight loss. It worsens a patient's quality of life and prognosis. In this study, the epidemiology of cachexia in lung cancer,
Takehito Shukuya, Kazuhisa Takahashi, Yasushi Shintani, Keita Miura, Ikuo Sekine, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Tomoya Kawaguchi, Nobuyuki Yamamoto, Etsuo Miyaoka, Ichiro Yoshino, Hiroshi Date   +13 more
doaj   +1 more source

Role of Complementary and Alternative Medicine in the Management of Cancer Cachexia

Asia-Pacific Journal of Oncology Nursing, 2021
Cancer cachexia is an important concern in cancer patients in view of advanced stage at presentation. The treatment goal for cachexia is the reversal of the loss of body weight and muscle mass with a variety of pharmacological agents.
Abhishek Shankar, Deepak Saini, Shubham Roy, Sachidanand Jee Bharati, Seema Mishra, Pritanjali Singh   +5 more
doaj   +1 more source

Cancer cachexia: Focus on cachexia factors and inter-organ communication

Chinese Medical Journal
. Cancer cachexia is a multi-organ syndrome and closely related to changes in signal communication between organs, which is mediated by cancer cachexia factors. Cancer cachexia factors, being the general name of inflammatory factors, circulating proteins,
Yongfei Wang, Zikai Dong, Ziyi An, Weilin Jin, Sihan Zhou, Xiuyuan Hao   +5 more
doaj   +1 more source

Oncology Update: Anamorelin

Palliative Care, 2017
Background: Cancer cachexia is a catabolic syndrome associated with uncontrolled muscle breakdown. There may be associated fat loss. Occurring in high frequency in advanced cancer, it is an indicator of poor prognosis.
Eric Prommer
doaj   +1 more source

Clinical Framework for Quality Improvement of Cancer Cachexia

Asia-Pacific Journal of Oncology Nursing, 2018
The objective of this article is to introduce the Clinical Framework for Quality Improvement of Cancer Cachexia (Cachexia Care Framework) as a tool to demonstrate the relevance of integrating the clinical components of cancer cachexia and the ...
Clara Granda-Cameron, Mary Pat Lynch
doaj   +1 more source